메뉴 건너뛰기




Volumn 64, Issue 8, 2017, Pages

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

Author keywords

antiangiogenesis; bevacizumab; irinotecan and temozolomide; neuroblastoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE;

EID: 85020644459     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26448     Document Type: Article
Times cited : (48)

References (43)
  • 1
    • 77957341503 scopus 로고    scopus 로고
    • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
    • Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334.
    • (2010) N Engl J Med. , vol.363 , Issue.14 , pp. 1324-1334
    • Yu, A.L.1    Gilman, A.L.2    Ozkaynak, M.F.3
  • 2
    • 84866623753 scopus 로고    scopus 로고
    • Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    • Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–3270.
    • (2012) J Clin Oncol , vol.30 , Issue.26 , pp. 3264-3270
    • Cheung, N.K.1    Cheung, I.Y.2    Kushner, B.H.3
  • 3
    • 0033554684 scopus 로고    scopus 로고
    • Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
    • Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165–1173.
    • (1999) Children's Cancer Group. N Engl J Med , vol.341 , Issue.16 , pp. 1165-1173
    • Matthay, K.K.1    Villablanca, J.G.2    Seeger, R.C.3
  • 4
    • 77953523121 scopus 로고    scopus 로고
    • Recent advances in neuroblastoma
    • Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211.
    • (2010) N Engl J Med , vol.362 , Issue.23 , pp. 2202-2211
    • Maris, J.M.1
  • 5
    • 1642535499 scopus 로고    scopus 로고
    • Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    • Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Can Res. 2004;10(1 Pt 1):84–87.
    • (2004) Clin Can Res , vol.10 , Issue.1 , pp. 84-87
    • Kushner, B.H.1    Kramer, K.2    Modak, S.3    Cheung, N.K.4
  • 6
    • 34247390662 scopus 로고    scopus 로고
    • Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    • Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24(33):5271–5276.
    • (2006) J Clin Oncol , vol.24 , Issue.33 , pp. 5271-5276
    • Kushner, B.H.1    Kramer, K.2    Modak, S.3    Cheung, N.K.4
  • 7
    • 79951975645 scopus 로고    scopus 로고
    • Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study
    • Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol. 2011;29(2):208–213.
    • (2011) J Clin Oncol , vol.29 , Issue.2 , pp. 208-213
    • Bagatell, R.1    London, W.B.2    Wagner, L.M.3
  • 8
    • 0035138511 scopus 로고    scopus 로고
    • A phase I study of irinotecan in pediatric patients: A pediatric oncology group study
    • Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Can Res. 2001;7(1):32–37.
    • (2001) Clin Can Res , vol.7 , Issue.1 , pp. 32-37
    • Blaney, S.1    Berg, S.L.2    Pratt, C.3
  • 9
    • 0142023876 scopus 로고    scopus 로고
    • A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors
    • Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21(20):3844–3852.
    • (2003) J Clin Oncol , vol.21 , Issue.20 , pp. 3844-3852
    • Vassal, G.1    Doz, F.2    Frappaz, D.3
  • 10
    • 35648981948 scopus 로고    scopus 로고
    • Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study
    • Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2007;25(29):4622–4627.
    • (2007) J Clin Oncol , vol.25 , Issue.29 , pp. 4622-4627
    • Bomgaars, L.R.1    Bernstein, M.2    Krailo, M.3
  • 11
    • 54449087562 scopus 로고    scopus 로고
    • A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
    • Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer. 2008;44(16):2453–2460.
    • (2008) Eur J Cancer , vol.44 , Issue.16 , pp. 2453-2460
    • Vassal, G.1    Giammarile, F.2    Brooks, M.3
  • 12
    • 13444259339 scopus 로고    scopus 로고
    • Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
    • Kushner BH, Kramer K, Modak S, Cheung NK. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer. 2005;103(4):858–862.
    • (2005) Cancer , vol.103 , Issue.4 , pp. 858-862
    • Kushner, B.H.1    Kramer, K.2    Modak, S.3    Cheung, N.K.4
  • 13
    • 34247337237 scopus 로고    scopus 로고
    • Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
    • Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol. 2006;24(33):5259–5264.
    • (2006) J Clin Oncol , vol.24 , Issue.33 , pp. 5259-5264
    • Rubie, H.1    Chisholm, J.2    Defachelles, A.S.3
  • 14
    • 0030698003 scopus 로고    scopus 로고
    • Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
    • Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem. 1997;272(42):26441–26447.
    • (1997) J Biol Chem , vol.272 , Issue.42 , pp. 26441-26447
    • Pourquier, P.1    Pilon, A.A.2    Kohlhagen, G.3    Mazumder, A.4    Sharma, A.5    Pommier, Y.6
  • 15
    • 10744231592 scopus 로고    scopus 로고
    • Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors
    • Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Can Res. 2004;10(3):840–848.
    • (2004) Clin Can Res , vol.10 , Issue.3 , pp. 840-848
    • Wagner, L.M.1    Crews, K.R.2    Iacono, L.C.3
  • 16
    • 0035951364 scopus 로고    scopus 로고
    • Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma
    • Ribatti D, Surico G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 2001;68(10):1161–1168.
    • (2001) Life Sci , vol.68 , Issue.10 , pp. 1161-1168
    • Ribatti, D.1    Surico, G.2    Vacca, A.3
  • 17
    • 34250710180 scopus 로고    scopus 로고
    • Prominent microvascular proliferation in clinically aggressive neuroblastoma
    • Peddinti R, Zeine R, Luca D, et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Can Res. 2007;13(12):3499–3506.
    • (2007) Clin Can Res , vol.13 , Issue.12 , pp. 3499-3506
    • Peddinti, R.1    Zeine, R.2    Luca, D.3
  • 18
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
    • (2003) Nat Med , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 19
    • 0035175686 scopus 로고    scopus 로고
    • Expression of angiogenic factors and tumor progression in human neuroblastoma
    • Komuro H, Kaneko S, Kaneko M, Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol. 2001;127(12):739–743.
    • (2001) J Cancer Res Clin Oncol , vol.127 , Issue.12 , pp. 739-743
    • Komuro, H.1    Kaneko, S.2    Kaneko, M.3    Nakanishi, Y.4
  • 20
    • 68549112845 scopus 로고    scopus 로고
    • The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients
    • Skoldenberg EG, Larsson A, Jakobson A, et al. The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients. Anticancer Res. 2009;29(8):3311–3319.
    • (2009) Anticancer Res , vol.29 , Issue.8 , pp. 3311-3319
    • Skoldenberg, E.G.1    Larsson, A.2    Jakobson, A.3
  • 21
    • 0036185180 scopus 로고    scopus 로고
    • VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells
    • Beierle EA, Strande LF, Chen MK. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg. 2002;37(3):467–471.
    • (2002) J Pediatr Surg , vol.37 , Issue.3 , pp. 467-471
    • Beierle, E.A.1    Strande, L.F.2    Chen, M.K.3
  • 22
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
    • (1997) Cancer Res , vol.57 , Issue.20 , pp. 4593-4599
    • Presta, L.G.1    Chen, H.2    O'Connor, S.J.3
  • 24
    • 38649105118 scopus 로고    scopus 로고
    • Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study
    • Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2008;26(3):399–405.
    • (2008) J Clin Oncol , vol.26 , Issue.3 , pp. 399-405
    • Glade Bender, J.L.1    Adamson, P.C.2    Reid, J.M.3
  • 25
    • 83055162488 scopus 로고    scopus 로고
    • Bevacizumab in pediatric patients: How safe is it?
    • de Pasquale MD, Castellano A, de Sio L, et al. Bevacizumab in pediatric patients: How safe is it? Anticancer Res. 2011;31(11):3953–3957.
    • (2011) Anticancer Res , vol.31 , Issue.11 , pp. 3953-3957
    • de Pasquale, M.D.1    Castellano, A.2    de Sio, L.3
  • 26
    • 84941348641 scopus 로고    scopus 로고
    • Safety of bevacizumab in patients younger than 4 years of age
    • Millan NC, Poveda MJ, Cruz O, Mora J. Safety of bevacizumab in patients younger than 4 years of age. Clin Transl Oncol. 2016;18(5):464–468.
    • (2016) Clin Transl Oncol , vol.18 , Issue.5 , pp. 464-468
    • Millan, N.C.1    Poveda, M.J.2    Cruz, O.3    Mora, J.4
  • 27
    • 84953351685 scopus 로고    scopus 로고
    • Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
    • Han K, Peyret T, Quartino A, et al. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol. 2016;81(1):148–160.
    • (2016) Br J Clin Pharmacol , vol.81 , Issue.1 , pp. 148-160
    • Han, K.1    Peyret, T.2    Quartino, A.3
  • 28
    • 34447121919 scopus 로고    scopus 로고
    • Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
    • Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Can Res. 2007;13(13):3942–3950.
    • (2007) Clin Can Res , vol.13 , Issue.13 , pp. 3942-3950
    • Dickson, P.V.1    Hamner, J.B.2    Sims, T.L.3
  • 29
    • 47549086112 scopus 로고    scopus 로고
    • Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease
    • Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery. 2008;144(2):269–275.
    • (2008) Surgery , vol.144 , Issue.2 , pp. 269-275
    • Sims, T.L.1    Williams, R.F.2    Ng, C.Y.3    Rosati, S.F.4    Spence, Y.5    Davidoff, A.M.6
  • 30
    • 43549097145 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts
    • Kaneko S, Ishibashi M, Kaneko M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts. Cancer Sci. 2008;99(6):1209–1217.
    • (2008) Cancer Sci , vol.99 , Issue.6 , pp. 1209-1217
    • Kaneko, S.1    Ishibashi, M.2    Kaneko, M.3
  • 31
    • 0027239723 scopus 로고
    • Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment
    • Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–1477.
    • (1993) J Clin Oncol , vol.11 , pp. 1466-1477
    • Brodeur, G.1    Pritchard, J.2    Berthold, F.3
  • 32
    • 33750483287 scopus 로고    scopus 로고
    • Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
    • Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47(7):865–874.
    • (2006) Pediatr Blood Cancer , vol.47 , Issue.7 , pp. 865-874
    • Messina, J.A.1    Cheng, S.C.2    Franc, B.L.3
  • 33
    • 81755171117 scopus 로고    scopus 로고
    • Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
    • Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol. 2011;29(33):4351–4357.
    • (2011) J Clin Oncol , vol.29 , Issue.33 , pp. 4351-4357
    • Park, J.R.1    Scott, J.R.2    Stewart, C.F.3
  • 35
    • 84895743330 scopus 로고    scopus 로고
    • Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study
    • Bagatell R, Norris R, Ingle AM, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833–839.
    • (2014) Pediatr Blood Cancer , vol.61 , Issue.5 , pp. 833-839
    • Bagatell, R.1    Norris, R.2    Ingle, A.M.3
  • 36
    • 84866734693 scopus 로고    scopus 로고
    • A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma
    • Furman WL, McGregor LM, McCarville MB, et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs. 2012;30(4):1660–1670.
    • (2012) Invest New Drugs , vol.30 , Issue.4 , pp. 1660-1670
    • Furman, W.L.1    McGregor, L.M.2    McCarville, M.B.3
  • 37
    • 84963799476 scopus 로고    scopus 로고
    • Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) trial
    • DuBois SG, Marachelian A, Fox E, et al. Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) trial. J Clin Oncol. 2016;34(12):1368–1375.
    • (2016) J Clin Oncol , vol.34 , Issue.12 , pp. 1368-1375
    • DuBois, S.G.1    Marachelian, A.2    Fox, E.3
  • 38
    • 84860538848 scopus 로고    scopus 로고
    • Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial
    • DuBois SG, Chesler L, Groshen S, et al. Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Can Res. 2012;18(9):2679–2686.
    • (2012) Clin Can Res , vol.18 , Issue.9 , pp. 2679-2686
    • DuBois, S.G.1    Chesler, L.2    Groshen, S.3
  • 40
    • 77954578108 scopus 로고    scopus 로고
    • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study
    • Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–3075.
    • (2010) J Clin Oncol , vol.28 , Issue.18 , pp. 3069-3075
    • Gururangan, S.1    Chi, S.N.2    Young Poussaint, T.3
  • 41
    • 84880337248 scopus 로고    scopus 로고
    • Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
    • Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr. Blood Cancer. 2013;60(9):1447–1451.
    • (2013) Pediatr. Blood Cancer , vol.60 , Issue.9 , pp. 1447-1451
    • Wagner, L.1    Turpin, B.2    Nagarajan, R.3    Weiss, B.4    Cripe, T.5    Geller, J.6
  • 42
    • 84893463503 scopus 로고    scopus 로고
    • Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab
    • Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr. Blood Cancer. 2014;61(4):756–759.
    • (2014) Pediatr. Blood Cancer , vol.61 , Issue.4 , pp. 756-759
    • Venkatramani, R.1    Malogolowkin, M.H.2    Mascarenhas, L.3
  • 43
    • 84887997111 scopus 로고    scopus 로고
    • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022)
    • Fangusaro J, Gururangan S, Poussaint TY, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013;119(23):4180–4187.
    • (2013) Cancer , vol.119 , Issue.23 , pp. 4180-4187
    • Fangusaro, J.1    Gururangan, S.2    Poussaint, T.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.